-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
